OptiBio Co., Ltd.

OptiBio is a South Korean in-vitro diagnostics company focused in researching, developing, and manufacturing cutting edge fluorescence immunoassay solutions. In 2020, OptiBio was selected by a research fund sponsored by the Bill & Melinda Gates foundation for its unique and dedicated approach to immunoassay.

OptiBio's competitive advantage stems from its strong foundation of experts, each specialized in fields crucial for product development. Our team is comprised of some of Korea's most talented scientists and engineers, dedicated to directly developing diagnostic markers, test kits, and analyzers. Our fundamental approach to specialization allows OptiBio to constantly improve our products, develop new test parameters, and respond to changing market needs. Including but not limited to inflammation, thyroids, cardiac and hormone, our test parameter ranges in 8 different categories offering up to more than 27 bio markers/test kits.

Shortly following the outbreak of Covid-19, OptiBio quicky developed the Optical Q SARS-CoV-2 neutralizing antibody (nAb) test kit and Rapid Q SARS-CoV-2 Antigen (Ag) rapid test kit.

OptiBio will continue to create, improve, and innovate world class diagnostic solutions in the field of fluorescence immunoassay and point-of-care testing (POCT). Through this, we aim to ultimately transform medical diagnosis into a universally available right.

Our mission

To expand point of care testing to ubiquity through disciplined research, milestone innovations, and a commitment to excellence.

Our vision

To transition the world to a place where no one suffers from medical misdiagnosis, delayed diagnosis, or a lack of access to diagnosis.